Neuphoria Therapeutics Inc. (NEUP)
| Market Cap | 22.95M |
| Revenue (ttm) | 15.66M |
| Net Income (ttm) | 5.83M |
| Shares Out | 1.88M |
| EPS (ttm) | 0.00 |
| PE Ratio | 3.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 180,899 |
| Open | 10.25 |
| Previous Close | 10.22 |
| Day's Range | 10.05 - 12.30 |
| 52-Week Range | 2.90 - 126.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 21.00 (+71.99%) |
| Earnings Date | Aug 28, 2025 |
About NEUP
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the α7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for NEUP stock is "Strong Buy" and the 12-month stock price target is $21.0.
News
Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments f...
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments fo...
Neuphoria Provides First Quarter 2025 Business Updates
BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments fo...
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans
Initiation by Merck of a Phase 2 trial in Alzheimer's disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company's pipeline diversification beyond BNC210 US $15M milesto...
Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025
BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology developing impactful treatments for neuropsy...
Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck
Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer's disease with MK-1167, an α7 nicotinic acetylcholine receptor positive allosteric modulator Milestone payment tr...
Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq
BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its previously announced scheme of arrangemen...